Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.00, for a total transaction of $15,475.00. Following the transaction, the chief financial officer owned 35,072 shares of the company’s stock, valued at approximately $876,800. This represents a 1.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Yajing Chen also recently made the following trade(s):

• On Friday, June 26th, Yajing Chen sold 2,264 shares of Zai Lab stock. The shares were sold at an average price of $17.46, for a total transaction of $39,529.44.

Zai Lab Stock Performance

ZLAB opened at $25.95 on Friday. The firm’s fifty day moving average is $19.58 and its two-hundred day moving average is $19.49. The firm has a market cap of $2.95 billion, a PE ratio of -15.18 and a beta of 0.78. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $36.77.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The firm had revenue of $106.31 million during the quarter. Equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Citigroup increased their price target on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Wall Street Zen cut Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Zacks Research upgraded Zai Lab from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.20.

Hedge Funds Weigh In On Zai Lab

An institutional investor recently raised its stake in Zai Lab stock. SG Americas Securities LLC raised its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. 41.65% of the stock is owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.